An artificial nanoemulsion carrying paclitaxel decreases the transplant heart vascular disease: A study in a rabbit graft model

Lourenço-Filho, Domingos D.; Maranhão, Raul C.; Mendez-Contreras, C.A.; Tavares, Elaine Rufo; Freitas, Fatima R.; Stolf, Noedir Antônio Groppo

doi:10.1016/j.jtcvs.2010.08.032

Cited by 29 publications

(25 citation statements)

References 22 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A more recent clinical study revealed that in heart transplants with very late rejection (> 7 years following transplantation), the presence of intravascular macrophages and donor specific antibodies are robust predictors of the development of more severe GVD [102]. Therapies effective in reducing GVD have also been shown to be associated with a significantly deceased macrophage infiltration [103,104]. These recent studies further confirmed that macrophages play a role in the pathogenesis of GVD.…”

Section: Macrophages In Gvdmentioning

confidence: 91%

Macrophages in solid organ transplantation

et al. 2014

View full text Add to dashboard Cite

Macrophages are highly plastic hematopoietic cells with diversified functions related to their anatomic location and differentiation states. A number of recent studies have examined the role of macrophages in solid organ transplantation. These studies show that macrophages can induce allograft injury but, conversely, can also promote tissue repair in ischemia-reperfusion injury and acute rejection. Therapeutic strategies that target macrophages to improve outcomes in solid organ transplant recipients are being examined in preclinical and clinical models. In this review, we discuss the role of macrophages in different types of injury and rejection, with a focus on macrophage-mediated tissue injury, specifically vascular injury, repair and remodeling. We also discuss emerging macrophage-centered therapeutic opportunities in solid organ transplantation.

show abstract

Section: Macrophages In Gvdmentioning

confidence: 91%

Macrophages in solid organ transplantation

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In animal studies, cholesterol-rich nanoemulsions (LDE) resembling LDL combined with paclitaxel (LDE-paclitaxel) injected intravenously were demonstrated to reduce intimal width and reduce destruction of the media [70]. This may be a promising strategy for further exploration in clinical studies.…”

Section: Future Trendsmentioning

confidence: 99%

Drugs for the Prevention and Treatment of Cardiac Allograft Vasculopathy

Gupta¹

2014

Cardiol Pharmacol

View full text Add to dashboard Cite

Cardiac allograft vasculopathy (CAV) of heart transplants is responsible for up to one-third of deaths at 5 years following cardiac transplantation. Risk factors for CAV include both traditional risk factors and immune factors. Drugs used for prevention and treatment of CAV include statins, calcium channel blockers and immunosuppressive agents. This review discusses the currently available drugs for CAV, the evidence behind their use, and future targets of therapy.

show abstract

“…LDE-paclitaxel treatment resulted in marked reduction of the stenosis of the grafts, width of the intima and destruction of the medium layer. It is remarkable that the treatment reduced sevenfold the macrophage invasion of the myocardium, which is a landmark of organ rejection [92].…”

Section: Doxorubicin (Anthracycline)mentioning

confidence: 99%